Arrow Mark Colorado Holdings LLC Atara Biotherapeutics, Inc. Transaction History

Arrow Mark Colorado Holdings LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$12.03 - $19.94 $609,620 - $1.01 Million	-50,675 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$19.05 - $41.04 $26,193 - $56,430	-1,375 Reduced 2.64%	50,675 $1.02 Million
Q1 2019 May 15, 2019	SELL	$28.4 - $41.74 $40.9 Million - $60.1 Million	-1,439,034 Reduced 96.51%	52,050 $2.07 Million
Q4 2018 Feb 14, 2019	SELL	$30.9 - $42.97 $362,364 - $503,909	-11,727 Reduced 0.78%	1,491,084 $51.8 Million
Q3 2018 Nov 14, 2018	BUY	$35.05 - $43.5 $8.65 Million - $10.7 Million	246,803 Added 19.65%	1,502,811 $62.1 Million
Q2 2018 Aug 14, 2018	SELL	$35.15 - $51.45 $6.29 Million - $9.21 Million	-179,011 Reduced 12.47%	1,256,008 $46.2 Million
Q1 2018 May 15, 2018	SELL	$18.0 - $48.35 $30.8 Million - $82.8 Million	-1,711,801 Reduced 54.4%	1,435,019 $56 Million
Q4 2017 Feb 14, 2018	BUY	$13.2 - $18.1 $4.9 Million - $6.72 Million	371,099 Added 13.37%	3,146,820 $57 Million
Q3 2017 Nov 14, 2017	BUY	$13.25 - $17.05 $36.8 Million - $47.3 Million	2,775,721	2,775,721 $45.9 Million

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Arrow Mark Colorado Holdings LLC, based on Form 13F filings with the SEC.

Stay updated on Arrow Mark Colorado Holdings LLC with notifications on news.